Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Assembly Biosciences, Inc (ASMB) operate in?
Assembly Biosciences, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Assembly Biosciences, Inc (ASMB) current stock price?
As of the latest data, Assembly Biosciences, Inc stock price is $30.01, with a previous close of $32.95. Assembly Biosciences, Inc lost -$2.94 in the last trading session, representing a -8.92% loss.
What is Assembly Biosciences, Inc (ASMB) current market capitalization?
Assembly Biosciences, Inc market cap is approximately 594.72 million.
What is Assembly Biosciences, Inc (ASMB) Earnings Per Share (EPS)?
The trailing EPS is $0.08, and the forward EPS is -$2.11.
What is Assembly Biosciences, Inc (ASMB) Price-to-Earnings (P/E) ratio?
Assembly Biosciences, Inc current P/E ratio is 375.13.
What is Assembly Biosciences, Inc (ASMB) EBITDA?
Assembly Biosciences, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.05 million.
Does Assembly Biosciences, Inc (ASMB) pay dividends?
No. Assembly Biosciences, Inc does not pay a dividend.
How did Assembly Biosciences, Inc (ASMB) perform in its most recent earnings report?
In the last report (June 30, 2026), Assembly Biosciences, Inc posted an EPS surprise of 15.63% and a revenue surprise of 18.19%.
What is Assembly Biosciences, Inc (ASMB) beta (volatility) score?
Assembly Biosciences, Inc has a beta of 1.092, meaning its volatility is roughly in line with the market.
